Applying an Artificial Intelligence-Enabled Electrocardiographic System for Reducing Mortality

Not Applicable

Completed

• Conditions: Intensity Care; Cardiovascular Diseases; Morality

• Registration Number: NCT05118035
• Lead Sponsor: National Defense Medical Center, Taiwan

Brief Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for early detection of clinical deterioration for reducing mortality.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-11-01
• Study First Submitted QC: 2021-11-01
• Study First Posted: 2021-11-11
• Study Start: 2021-12-15
• Primary Completion: 2022-04-30
• Study Completion: 2022-12-31
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-03
• Last Update Posted: 2023-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15965

Inclusion Criteria

• Patients in emergency department or inpatient department.
• Patients recieved at least 1 ECG examination.

Exclusion Criteria

• The patients recieved ECG at the period of inactive AI-ECG system.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
All cause mortality (death)	Within 90 days	After performing an electrocardiogram, the patient's survival is tracked.

Secondary Outcome Measures

Name	Time	Method
Cardiovascular cause mortality (death)	Within 90 days	After performing an electrocardiogram, the patient's survival is tracked.
Arrhythmia medication	Within 12 hours	After performing an electrocardiogram, the patient recieved related intervention.
Electrolyte examination	Within 3 days	After performing an electrocardiogram, the patient recieved electrolyte examination
Cadiac examination	Within 3-7 days	After performing an electrocardiogram, the patient recieved cadiac examination

Trial Locations

Locations (1)

National Defense Medical Center; 🇨🇳 Taipei, Taiwan